EU­'s phar­ma leg­isla­tive re­forms 'will scare in­vest­ment away,' Astel­las ex­ec­u­tive says

Eu­rope is on the brink of wrap­ping up its first ma­jor le­gal and reg­u­la­to­ry re­forms for the phar­ma in­dus­try in about two decades, but some in in­dus­try are say­ing the re­forms may not make the con­ti­nent more at­trac­tive for R&D in­vest­ment.

Be­gin­ning April 10, mem­bers of the Eu­ro­pean Par­lia­ment are sched­uled to de­bate and vote on the leg­isla­tive over­haul at a ple­nary ses­sion. The new reg­u­la­tion and di­rec­tive are meant to make Eu­rope a more at­trac­tive des­ti­na­tion for R&D. And while there’s a lot in the pack­age to be thank­ful for, Claus Ziel­er, chief com­mer­cial of­fi­cer at Astel­las and board rep­re­sen­ta­tive of in­dus­try group EF­PIA, told End­points News in an in­ter­view on Mon­day that the low­er­ing of the da­ta pro­tec­tion pe­ri­od to six months less than what phar­ma com­pa­nies cur­rent­ly en­joy is a non-starter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER